Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (11-20 of 325) with videos related to

Pageof 33
Sort By:
Cancer Cell|April 11, 2025
AI-driven biomarkers for antibody-drug conjugatesSherene Loi, Roberto Salgado
The Lancet. Oncology|October 10, 2025
Whole-genome sequencing in breast cancer: is it ready for clinical application?Peter Savas, Sherene Loi
The Lancet. Oncology|December 14, 2017
Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevanceRoberto Salgado, Sherene Loi
Breast (Edinburgh, Scotland)|July 3, 2017
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)Lironne Wein, Sherene Loi
Immunotherapy|October 8, 2014
Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapyPeter Savas, Sherene Loi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as SweetRoberto Salgado, Sherene Loi
Cold Spring Harbor Perspectives in Medicine|April 3, 2023
Immunotherapy Approaches for Breast Cancer Patients in 2023Leisha A Emens, Sherene Loi
Breast (Edinburgh, Scotland)|December 17, 2019
Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC)Elizabeth F Blackley, Sherene Loi
Breast (Edinburgh, Scotland)|January 8, 2022
Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 updateLauren C Brown, Sherene Loi
Chinese Clinical Oncology|November 22, 2017
Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancerStephen J Luen, Sherene Loi
Pageof 33

Showing results (11-20 of 325) with videos related to

Sort By:
Pageof 33
Cancer Cell|April 11, 2025
AI-driven biomarkers for antibody-drug conjugatesSherene Loi, Roberto Salgado
The Lancet. Oncology|October 10, 2025
Whole-genome sequencing in breast cancer: is it ready for clinical application?Peter Savas, Sherene Loi
The Lancet. Oncology|December 14, 2017
Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevanceRoberto Salgado, Sherene Loi
Breast (Edinburgh, Scotland)|July 3, 2017
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)Lironne Wein, Sherene Loi
Immunotherapy|October 8, 2014
Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapyPeter Savas, Sherene Loi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as SweetRoberto Salgado, Sherene Loi
Cold Spring Harbor Perspectives in Medicine|April 3, 2023
Immunotherapy Approaches for Breast Cancer Patients in 2023Leisha A Emens, Sherene Loi
Breast (Edinburgh, Scotland)|December 17, 2019
Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC)Elizabeth F Blackley, Sherene Loi
Breast (Edinburgh, Scotland)|January 8, 2022
Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 updateLauren C Brown, Sherene Loi
Chinese Clinical Oncology|November 22, 2017
Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancerStephen J Luen, Sherene Loi
Pageof 33